Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lamivudine + zidovudine + nevirapine is a fixed-dose combination antiretroviral medication used for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg. It contains two nucleoside analogue reverse transcriptase inhibitors (lamivudine and zidovudine) and one non-nucleoside reverse transcriptase inhibitor (nevirapine). Lamivudine and zidovudine inhibit HIV reverse transcription by causing viral DNA chain termination, while nevirapine binds directly to reverse transcriptase, causing a conformational change that inhibits its activity. This combination reduces the amount of virus in the body, increases CD4 cell counts, and slows disease progression. It is not curative but helps manage HIV infection[1][2][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lamivudine + zidovudine + nevirapine.